Tauni Carter
Medical · Keizer, ORNPI 1811292170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$860
- Lilly USA, LLC$570
- Amgen$434
- Sanofi-aventis U.S. LLC$366
- Xeris Pharmaceuticals, Inc.$338
- AstraZeneca$282
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,76899%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $860 |
| Lilly USA, LLC | 31 | $570 |
| Amgen(2 entities) | 18 | $434 |
| Sanofi-aventis U.S. LLC | 10 | $366 |
| Xeris Pharmaceuticals, Inc. | 18 | $338 |
| AstraZeneca(2 entities) | 15 | $282 |
| Boehringer Ingelheim | 10 | $241 |
| Abbott | 12 | $225 |
| Bayer | 9 | $172 |
| Amryt Pharma Holdings Ltd | 6 | $140 |
| Novartis | 5 | $122 |
| Dexcom, Inc. | 7 | $117 |
| Vistapharm, Inc. | 7 | $114 |
| Zealand Pharma US, Inc. | 6 | $106 |
| Medtronic | 5 | $103 |
| Chiasma, Inc. | 2 | $89 |
| Amarin Pharma, Inc. | 3 | $66 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Mannkind Corporation | 3 | $59 |
| Radius Health, Inc. | 3 | $55 |
| Merck | 3 | $53 |
| Astellas Pharma US Inc | 2 | $51 |
| Lifescan, Inc. | 3 | $48 |
| Pfizer | 2 | $35 |
| Echosens North America, Inc. | 2 | $29 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| AbbVie | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$127
How this compares
$4,833 in reported general payments places this provider in the 95th percentile of 364 medical providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 374 | $473,247 |
| MounjaroTirzepatide | 275 | $345,665 |
| JardianceEmpagliflozin | 172 | $189,401 |
| TrulicityDulaglutide | 82 | $101,384 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 59 | $69,089 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $62,966 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $61,233 |
| FarxigaDapagliflozin Propanediol | 61 | $56,596 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $53,034 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $50,098 |
| GenotropinSomatropin | 16 | $37,648 |
| LyumjevInsulin Lispro-Aabc | 21 | $37,243 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $30,515 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $23,125 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $21,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $570 | $492,387414 claims |
| Novo NordiskOzempic, Novolog | $860 | $477,698389 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $241 | $273,909247 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $366 | $61,23358 claims |
| AstraZenecaFarxiga | $282 | $56,59661 claims |
| PfizerGenotropin | $35 | $37,64816 claims |
| MerckJanuvia | $53 | $20,64920 claims |
| AbbVieSynthroid | $15 | $2,06234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 364 medical providers in Oregon.
Other medical in Keizer
- Mark DavisLake Oswego$12K
- Britt BennPortland$11K
- Benjamin WillettSalem$11K
- Jeffrey RennaSalem$9K
- Christy SnoSpringfield$8K
- Erica BallardPortland$8K
- Nicole WydraCorvallis$8K
- Caitlyn EricksonHillsboro$6K
- Brolin JohnsonSalem$6K
- Maci PfaffenbergerGresham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.